Ken Griffin Kiromic Biopharma, Inc. Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.26 - $10.2 $5,244 - $205,744	20,171 Added 102.42%	39,865 $12,000
Q2 2022 Aug 15, 2022	BUY	$0.26 - $0.87 $2,342 - $7,837	9,009 Added 84.31%	19,694 $9,000
Q1 2022 May 16, 2022	SELL	$0.6 - $1.82 $19,579 - $59,392	-32,633 Reduced 75.33%	10,685 $9,000
Q4 2021 Feb 14, 2022	BUY	$1.53 - $3.12 $25,451 - $51,901	16,635 Added 62.34%	43,318 $66,000
Q3 2021 Nov 15, 2021	BUY	$2.69 - $4.94 $13,337 - $24,492	4,958 Added 22.82%	26,683 $82,000
Q1 2021 May 17, 2021	BUY	$8.2 - $11.81 $82,721 - $119,139	10,088 Added 86.69%	21,725 $203,000
Q4 2020 Feb 16, 2021	BUY	$8.11 - $11.5 $94,376 - $133,825	11,637 New	11,637 $97,000

107K

Ticker KRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,843,200
Market Cap $22.2M
Description
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate tar...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.